Tag: casodex
SIGN UP FOR OUR NEWS LETTER


Quick Search

Reset

Testosterone Inactivating Pharmaceuticals

Tue 30 Nov 2010

By Mark Scholz, M.D., Prostate Oncology Specialists Edited from PCRI Insights November, 2010 v 13.4 For print friendly version, download the PDF for this article Prostate cancer needs testosterone to survive. Blocking testosterone is proven to prolong life in randomized prospective trials. Testosterone Inactivating Pharmaceuticals (TIP), otherwise known as androgen deprivation or hormone blockade, areRead More ›

Anti-androgen Monotherapy

Fri 1 Oct 2010

By: Mark Scholz, M.D. Prostate Oncology Specialists October 2010 Traditionally, anti-androgen medications have been used in combination with LHRH agonists to block testosterone. When anti-androgens are used alone, as so-called anti-androgen monotherapy, it causes in a milder degree of testosterone blockade. There are three anti-androgens—bicalutamide, flutamide, and nilutamide. They work by keeping testosterone away fromRead More ›

Androgen Resistance, Part 2

Sat 1 Feb 2003

Reprinted from PCRI Insights February 2003 v 6.1 By Charles E. (Snuffy) Myers, M.D., Founder and Medical Director, The American Institute for Diseases of the Prostate, Charlottesville, VA, and Member of the PCRI Medical Advisory Board    Part 1 of this article                                Part 3 of this article   Treatment Options for Androgen Hypersensitization: Antiandrogens In Part 1Read More ›

Androgen Resistance, Part 1

Fri 1 Nov 2002

Reprinted from PCRI Insights November 2002 v 5.2 By Charles E. (Snuffy) Myers, M.D., Founder and Medical Director, The American Institute for Diseases of the Prostate, Charlottesville, VA, and Member of the PCRI Medical Advisory Board   Introduction The development of hormone resistance is the event most patients with prostate cancer (PC) fear most. TheyRead More ›

How Do You Treat Prostate Cancer That Has Progressed On Primary Androgen Deprivation Therapy? Part 2 of 2: Secondary Hormonal Treatment Approaches

Thu 1 Oct 1998

Revised October 1998     TABLE OF CONTENTS – PART 2 Page(s) Table of Contents 4 Overview 5 The antiandrogen withdrawal response (AAWR) 5-6 High-dose bicalutamide after flutamide withdrawal 6-7 High-dose ketoconazole (HDK) with hydrocortisone (HC) 7-13 Aminoglutethimide (AG) with hydrocortisone (HC) 12-13 Megestrol acetate 13-15 Corticosteroids 16 Estrogen therapy 17-18 Summary and a viewRead More ›